Cargando…
Minocycline and doxycycline therapy in community patients with rheumatoid arthritis: prescribing patterns, patient-level determinants of use, and patient-reported side effects
INTRODUCTION: Minocycline and doxycycline are safe and moderately effective disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of early, DMARD-naïve rheumatoid arthritis (RA), although little is known about their use outside clinical trials. We characterize the use of minocycline and d...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3308103/ https://www.ncbi.nlm.nih.gov/pubmed/22008667 http://dx.doi.org/10.1186/ar3491 |
_version_ | 1782227397564694528 |
---|---|
author | Smith, Christopher J Sayles, Harlan Mikuls, Ted R Michaud, Kaleb |
author_facet | Smith, Christopher J Sayles, Harlan Mikuls, Ted R Michaud, Kaleb |
author_sort | Smith, Christopher J |
collection | PubMed |
description | INTRODUCTION: Minocycline and doxycycline are safe and moderately effective disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of early, DMARD-naïve rheumatoid arthritis (RA), although little is known about their use outside clinical trials. We characterize the use of minocycline and doxycycline in community-dwelling RA patients by examining associated prescribing patterns, patient-level determinants of use, and side-effect profiles. METHODS: We studied 15,716 patients with RA observed between 1998 and 2009 while participating in a long-term US observational study. RESULTS: Minocycline or doxycycline was prescribed by 18% of rheumatologists (interquartile range one to two patients per physician) to 9% of RA patients. Significant differences between minocycline-treated and doxycycline-treated patients and nontreated patients included age (58.4 years vs. 59.8 years), RA duration (14.8 years vs. 13.7 years), Caucasian race (93.7% vs. 89.7%), lifetime DMARDs and biologics (3.3 vs. 2.5), prednisone use (40.1% vs. 35.3%), and Medical Outcomes Study 36-Item Short Form Survey physical component summary score (35.0 vs. 36.4). In multivariable Cox regression, patients initiating minocycline or doxycycline had increased disease activity, more comorbidities, and a greater number of prior nonbiologic DMARDs. Side effects were reported by 17.8% of minocycline users and 11.8% of doxycycline users. Skin complaints accounted for 54% of minocycline patient-reported side effects. The most commonly effected organ systems for doxycycline were gastrointestinal (35.4%) and skin (33.7%). Approximately 75% of side effects were of mild or moderate severity. CONCLUSIONS: Rheumatologists have not embraced minocycline or doxycycline as primary treatment options for RA and reserve their use primarily in patients with long-standing, refractory disease. These drugs are generally well tolerated, with skin complaints, nausea, and dizziness being the most common patient-reported side effects. |
format | Online Article Text |
id | pubmed-3308103 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-33081032012-03-20 Minocycline and doxycycline therapy in community patients with rheumatoid arthritis: prescribing patterns, patient-level determinants of use, and patient-reported side effects Smith, Christopher J Sayles, Harlan Mikuls, Ted R Michaud, Kaleb Arthritis Res Ther Research Article INTRODUCTION: Minocycline and doxycycline are safe and moderately effective disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of early, DMARD-naïve rheumatoid arthritis (RA), although little is known about their use outside clinical trials. We characterize the use of minocycline and doxycycline in community-dwelling RA patients by examining associated prescribing patterns, patient-level determinants of use, and side-effect profiles. METHODS: We studied 15,716 patients with RA observed between 1998 and 2009 while participating in a long-term US observational study. RESULTS: Minocycline or doxycycline was prescribed by 18% of rheumatologists (interquartile range one to two patients per physician) to 9% of RA patients. Significant differences between minocycline-treated and doxycycline-treated patients and nontreated patients included age (58.4 years vs. 59.8 years), RA duration (14.8 years vs. 13.7 years), Caucasian race (93.7% vs. 89.7%), lifetime DMARDs and biologics (3.3 vs. 2.5), prednisone use (40.1% vs. 35.3%), and Medical Outcomes Study 36-Item Short Form Survey physical component summary score (35.0 vs. 36.4). In multivariable Cox regression, patients initiating minocycline or doxycycline had increased disease activity, more comorbidities, and a greater number of prior nonbiologic DMARDs. Side effects were reported by 17.8% of minocycline users and 11.8% of doxycycline users. Skin complaints accounted for 54% of minocycline patient-reported side effects. The most commonly effected organ systems for doxycycline were gastrointestinal (35.4%) and skin (33.7%). Approximately 75% of side effects were of mild or moderate severity. CONCLUSIONS: Rheumatologists have not embraced minocycline or doxycycline as primary treatment options for RA and reserve their use primarily in patients with long-standing, refractory disease. These drugs are generally well tolerated, with skin complaints, nausea, and dizziness being the most common patient-reported side effects. BioMed Central 2011 2011-10-18 /pmc/articles/PMC3308103/ /pubmed/22008667 http://dx.doi.org/10.1186/ar3491 Text en Copyright ©2011 Smith et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Smith, Christopher J Sayles, Harlan Mikuls, Ted R Michaud, Kaleb Minocycline and doxycycline therapy in community patients with rheumatoid arthritis: prescribing patterns, patient-level determinants of use, and patient-reported side effects |
title | Minocycline and doxycycline therapy in community patients with rheumatoid arthritis: prescribing patterns, patient-level determinants of use, and patient-reported side effects |
title_full | Minocycline and doxycycline therapy in community patients with rheumatoid arthritis: prescribing patterns, patient-level determinants of use, and patient-reported side effects |
title_fullStr | Minocycline and doxycycline therapy in community patients with rheumatoid arthritis: prescribing patterns, patient-level determinants of use, and patient-reported side effects |
title_full_unstemmed | Minocycline and doxycycline therapy in community patients with rheumatoid arthritis: prescribing patterns, patient-level determinants of use, and patient-reported side effects |
title_short | Minocycline and doxycycline therapy in community patients with rheumatoid arthritis: prescribing patterns, patient-level determinants of use, and patient-reported side effects |
title_sort | minocycline and doxycycline therapy in community patients with rheumatoid arthritis: prescribing patterns, patient-level determinants of use, and patient-reported side effects |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3308103/ https://www.ncbi.nlm.nih.gov/pubmed/22008667 http://dx.doi.org/10.1186/ar3491 |
work_keys_str_mv | AT smithchristopherj minocyclineanddoxycyclinetherapyincommunitypatientswithrheumatoidarthritisprescribingpatternspatientleveldeterminantsofuseandpatientreportedsideeffects AT saylesharlan minocyclineanddoxycyclinetherapyincommunitypatientswithrheumatoidarthritisprescribingpatternspatientleveldeterminantsofuseandpatientreportedsideeffects AT mikulstedr minocyclineanddoxycyclinetherapyincommunitypatientswithrheumatoidarthritisprescribingpatternspatientleveldeterminantsofuseandpatientreportedsideeffects AT michaudkaleb minocyclineanddoxycyclinetherapyincommunitypatientswithrheumatoidarthritisprescribingpatternspatientleveldeterminantsofuseandpatientreportedsideeffects |